Accepted Manuscript

Considerations for biomarker-targeted intervention strategies for TB prevention

Andrew Fiore-Gartland, Lindsay N. Carpp, Kogieleum Naidoo, Ethan Thompson, Daniel E. Zak, Steve Self, Gavin Churchyard, Gerhard Walzl, Adam Penn-Nicholson, Thomas J. Scriba, Mark Hatherill

Tuberculosis

Tuberculosis

Fermina a consequence de la consequence del consequence de la consequence

PII: S1472-9792(17)30389-X

DOI: 10.1016/j.tube.2017.11.009

Reference: YTUBE 1648

To appear in: Tuberculosis

Received Date: 15 September 2017
Revised Date: 17 November 2017
Accepted Date: 21 November 2017

Please cite this article as: Fiore-Gartland A, Carpp LN, Naidoo K, Thompson E, Zak DE, Self S, Churchyard G, Walzl G, Penn-Nicholson A, Scriba TJ, Hatherill M, Considerations for biomarker-targeted intervention strategies for TB prevention, *Tuberculosis* (2017), doi: 10.1016/j.tube.2017.11.009.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

1	Considerations for biomarker-targeted intervention strategies for TB prevention
2	
3	Andrew Fiore-Gartland ^{a,*} , Lindsay N. Carpp ^a , Kogieleum Naidoo ^b , Ethan Thompson ^c , Daniel E. Zak ^c ,
4	Steve Self ^a , Gavin Churchyard ^{d,e,f} , Gerhard Walzl ^g , Adam Penn-Nicholson ^h , Thomas J Scriba ^h , Mark
5	Hatherill ^h
6	
7	^a Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview
8	Ave N, Seattle, WA 98109, USA
9	^b Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, Medical Research
10	Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research
11	Institute, University of KwaZulu-Natal, Durban, South Africa
12	^c Center for Infectious Disease Research, 307 Westlake Ave N #500, Seattle, WA 98109, USA
13	^d The Aurum Institute, Johannesburg, 29 Queens Road, Parktown Johannesburg, Gauteng, 2193
14	South Africa
15	^e School of Public Health, University of Witwatersrand, Johannesburg, South Africa
16	^f Advancing Treatment and Care for Tuberculosis and HIV, South African Medical Research Council,
17	Johannesburg, South Africa
18	⁹ DST/NRF Centre of Excellence for Biomedical TB Research and SAMRC Centre for TB Research,
19	Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of
20	Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
21	^h South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine,
22	Division of Immunology, Department of Pathology, University of Cape Town, South Africa
23	
24	E-mail addresses: AFG, agartlan@scharp.org; LNC, lcarpp@fredhutch.org; KN,
25	Kogie.Naidoo@caprisa.org; DEZ, daniel.zak@cidresearch.org; SS, sself@fredhutch.org; GC,
26	gchurchyard@auruminstitute.org; GW, gwalzl@sun.ac.za; AP-N, adam.penn-nicholson@uct.ac.za;
27	TJS, thomas.scriba@uct.ac.za; MH, mark.hatherill@uct.ac.za
28	
29	* Corresponding author. E-mail: agartlan@fredhutch.org. Vaccine and Infectious Disease Division,
30	Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA. Tel: (206)
31	667-1228, Fax: (206) 667-4812.
32	

Abbreviations: 3HP, 12-dose once-weekly rifapentine 900 mg plus isoniazid 900 mg; ACS, Adolescent

Cohort Study; COR, correlate of risk; CORTIS, Correlate of Risk Targeted Intervention Study; IGRA,

33

34

1

Download English Version:

https://daneshyari.com/en/article/8485167

Download Persian Version:

https://daneshyari.com/article/8485167

<u>Daneshyari.com</u>